Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1208

Sort by

Sort Order Select

Journal Articles

Cytokines and costimulation in acute graft-versus-host disease

Geoffrey R. Hill, Motoko Koyama

Blood (2020) 136 (4): 418–428.

https://doi.org/10.1182/blood.2019000952

Published: 2020

Journal Articles

CD28 fusions: an opportunity for young ATL?

Lucy B. M. Cook, Aileen G. Rowan

Blood (2020) 135 (17): 1415–1416.

https://doi.org/10.1182/blood.2020004958

Published: 2020

Journal Articles

Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions

Noriaki Yoshida, Kay Shigemori, Nicholas Donaldson, Christopher Trevisani, Nicolas A. Cordero, Kristen E. Stevenson, Xia Bu, Fumiko Arakawa, Mai Takeuchi, Koichi Ohshima, Akinori Yoda, Samuel Y. Ng, David M. Weinstock

Blood (2020) 135 (17): 1467–1471.

https://doi.org/10.1182/blood.2019001815

Published: 2020

Includes: Supplemental data

Journal Articles

Beat pediatric ALL MRD: CD28 CAR T and transplant

Marco Ruella, Frederick L. Locke

Blood (2019) 134 (26): 2333–2335.

https://doi.org/10.1182/blood.2019003821

Published: 2019

Journal Articles

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Benjamin Watkins, Yvonne Suessmuth, Kayla Betz, BS, Alison Yu, PhD, Brandi Bratrude, Muna Qayed, MD MSc, Kathryn Pellegrini, Steven Bosinger, Amelia Langston, MD, John T. Horan, MDMPH, Bruce R. Blazar, MD, Leslie Kean, MD PhD

Blood (2019) 134 (Supplement_1): 596.

https://doi.org/10.1182/blood-2019-131955

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Xiaowen Tang, Liqing Kang, Wei Qi, Wei Cui, Haiping Dai, Zheng Li, Jia Yin, Changju Qu, PhD, Ting Xu, Xiaming Zhu, Lei Yu, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1338.

https://doi.org/10.1182/blood-2019-127890

Published: 2019

Journal Articles

Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia

Lu Tang, Heng Mei, PhD MD, Yu Hu, MD PhD, Zhinan Yin, PhD MD, Huiwen Jiang, Chenggong Li, Min Xu

Blood (2019) 134 (Supplement_1): 1399.

https://doi.org/10.1182/blood-2019-130354

Published: 2019

Journal Articles

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Masahiro Suto, Eri Matsuki, MD, Erika Sekiguchi, Hiroya Tamaki, MD PhD, Isao Tawara, MD PhD, Grace Chen, MD PhD, Kenichi Ishizawa, MD PhD, Pavan Reddy, Tomomi Toubai

Blood (2019) 134 (Supplement_1): 1926.

https://doi.org/10.1182/blood-2019-123875

Published: 2019

Journal Articles

Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

Biping Deng, BS, MD, Jing Pan, Shuangyou Liu, Yuehui Lin, Zhaoli Liu, Yunlong Chen, Xiaoming Qu, Yu 'e Zhang, Zhongxin Zhang, Xuansha Niu, Ming Ma, Tong Wu, MD, Alex Hong Chang, Chunrong Tong

Blood (2019) 134 (Supplement_1): 1957.

https://doi.org/10.1182/blood-2019-126695

Published: 2019

Journal Articles

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

Katia Beider, Valeria Voevoda, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Ivetta Danilesko, MD, Ania Hava Grushchenko-Polaq, Olivia Devillers, Idit Wolf, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 1989.

https://doi.org/10.1182/blood-2019-129619

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Nadia El Khawanky, Bsc(Biomed), BHlthSc(Hons), Amy Hughes, PhD, Wenbo Yu, PhD, Sanaz Taromi, PhD, Jade Clarson, BSc, Angel F. Lopez, MD PhD, Michael P. Brown, MD PhD, Justus Duyster, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Deborah L. White, PhD FFSc (RCPA), Agnes S. M. Yong, MD PhD, Robert Zeiser, MD

Blood (2019) 134 (Supplement_1): 3904.

https://doi.org/10.1182/blood-2019-124684

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential

Jibran Durrani, Hassan Awada, Ashwin Kishtagari, MBBS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, Sanghee Hong, MD, Sunisa Kongkiatkamon, Alan Lichtin, MD, Aziz Nazha, MD, Bhumika J. Patel, MD, Yogenthiran Saunthararajah, MD, Hetty E. Carraway, MD MBA, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 3743.

https://doi.org/10.1182/blood-2019-129330

Published: 2019

Journal Articles

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, MD PhD, Sutapa Sinha, PhD, Raphael Mwangi, MS, Nancy Scott, MS, Mehrdad Hefazi, MD, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 3868.

https://doi.org/10.1182/blood-2019-129349

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Tanya Siddiqi, MD, Xiuli Wang, PhD, Joycelynne Palmer, PhD, Leslie L. Popplewell, MD FRCPA, Liana Nikolaenko, MD, Alex F. Herrera, MD, Lihua E Budde, MD PhD, Laura Lim, Vibhuti Vyas, MS, Christine E Brown, PhD, Stephen J. Forman, MD

Blood (2019) 134 (Supplement_1): 4075.

https://doi.org/10.1182/blood-2019-123765

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Cytokines and costimulation in acute graft-versus-host disease

CD28 fusions: an opportunity for young ATL?

Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions

Beat pediatric ALL MRD: CD28 CAR T and transplant

Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Tandem CAR T Cells Targeting CD19 and CD22 Is a Safe and Highly Efficacious Treatment for Relapse/ Refractory ALL Patients

Signatures of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Patients with Acute Myeloid Leukemia

NLRP6 in Donor T Cells Separately Regulates CD4 and CD8 Mediated Graft-Versus-Host Disease in Experimental Murine BMT

Leukemia Burden in Peripheral Blood Has Negative Impact on CD19-CART Cell Culture and Its Clinical Efficacy in Patients with Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

Immunophenotyping and Function of Peripheral Blood Mononuclear Cells in Patients Undergoing Unrelated Allogeneic Transplantation with Post-Transplantation Cyclophosphamide in Combination with ATG Anti-Graft Versus Host Disease Prophylaxis

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only